Servier announced a definitive agreement to acquire Day One Biopharmaceuticals for roughly $2.5 billion, securing the pediatric glioma drug Ojemda and multiple investigational oncology programs. The companies said the deal, expected to close in Q2, will be funded through a mix of existing cash and investments and reflects a ~68% premium to Day One’s closing price prior to the announcement. Day One generated roughly $155 million in sales from Ojemda in 2025, and Servier plans to integrate the asset with its existing glioma franchise that includes Voranigo. The transaction gives Servier immediate commercial presence in rare pediatric brain tumors and access to Day One’s R&D pipeline spanning pediatric and adult solid tumors. Servier emphasized continuity of development and expanded R&D capacity; Day One’s executive team framed the sale as a way to accelerate the company’s mission to serve patients across ages. Financial terms and strategic fit were highlighted by both firms; regulators and payers will now be central to near-term integration planning.